ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Sagimet Biosciences Inc. (SGMT) stock declined over -6.73%, trading at $1.94 on NASDAQ, down from the previous close of $2.08. The stock opened at $1.91, fluctuating between $1.73 and $1.97 in the recent session.
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Employees | 14 |
Beta | 2.62 |
Sales or Revenue | N/A |
5Y Sales Change% | 0% |
Fiscal Year Ends | N/A |
Sector | Healthcare |
Industry | Biotechnology |